DK0510949T3 - Cytomoduleret konjugat indeholdende specifikke bindingspar. - Google Patents

Cytomoduleret konjugat indeholdende specifikke bindingspar.

Info

Publication number
DK0510949T3
DK0510949T3 DK92303618.0T DK92303618T DK0510949T3 DK 0510949 T3 DK0510949 T3 DK 0510949T3 DK 92303618 T DK92303618 T DK 92303618T DK 0510949 T3 DK0510949 T3 DK 0510949T3
Authority
DK
Denmark
Prior art keywords
cytomodulated
specific binding
binding pairs
containing specific
conjugates
Prior art date
Application number
DK92303618.0T
Other languages
Danish (da)
English (en)
Inventor
Philippe Pouletty
Original Assignee
Sangstat Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24772845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0510949(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sangstat Medical Corp filed Critical Sangstat Medical Corp
Application granted granted Critical
Publication of DK0510949T3 publication Critical patent/DK0510949T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
DK92303618.0T 1991-04-23 1992-04-22 Cytomoduleret konjugat indeholdende specifikke bindingspar. DK0510949T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69053091A 1991-04-23 1991-04-23

Publications (1)

Publication Number Publication Date
DK0510949T3 true DK0510949T3 (da) 1997-07-28

Family

ID=24772845

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92303618.0T DK0510949T3 (da) 1991-04-23 1992-04-22 Cytomoduleret konjugat indeholdende specifikke bindingspar.

Country Status (7)

Country Link
EP (1) EP0510949B2 (fr)
JP (1) JP3105629B2 (fr)
AT (1) ATE147993T1 (fr)
CA (1) CA2066810A1 (fr)
DE (1) DE69216899T3 (fr)
DK (1) DK0510949T3 (fr)
ES (1) ES2099211T5 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858363A (en) * 1990-07-20 1999-01-12 Pharmacia & Upjohn Ab Target specific antibody-superantigen conjugates and their preparation
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
EP0602290B1 (fr) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antigène de surface du virus de l'hépatite B conjugué à des anticorps et utilisation d'un tel conjugué
JPH10511989A (ja) * 1996-04-10 1998-11-17 サングスタット メディカル コーポレイション 特異的結合ペア構成要素の細胞調節性複合体
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6096725A (en) * 1997-07-02 2000-08-01 Neose Technologies, Inc. Methods of using αGal oligosaccharides as immune system targeting agents
GB9724838D0 (en) * 1997-11-26 1998-01-21 Franks Christopher R Compositions
CN1320044A (zh) 1998-08-11 2001-10-31 Idec药物公司 包括施用抗－cd20抗体的b－细胞淋巴瘤联合疗法
ES2543819T3 (es) * 1998-11-09 2015-08-24 Biogen Inc. Tratamiento de neoplasias hematológicas asociadas con células tumorales circulantes utilizando anticuerpo quimérico dirigido contra CD20
JP2002539076A (ja) * 1999-01-06 2002-11-19 ユニバーシティ・オブ・サザン・カリフォルニア 新脈管形成抑制のための方法および組成物
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
ATE435031T1 (de) 1999-07-13 2009-07-15 Univ Southern California Methode und zusammensetzung zur angiogenese- inhibierung mit antagonisten gegen mmp-9 und beta1-integrine
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
MXPA02009454A (es) 2000-03-31 2003-04-10 Purdue Research Foundation Metodo de tratamiento usando conjugados ligando-inmunogeno.
KR20040058229A (ko) 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US7488792B2 (en) 2002-08-28 2009-02-10 Burnham Institute For Medical Research Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
KR101329843B1 (ko) 2002-11-15 2013-11-14 젠맵 에이/에스 Ｃｄ25에 대한 인간 모노클로날 항체
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
EP1594898A2 (fr) 2003-02-06 2005-11-16 Tripep AB Echangeurs de specificite glycosyles
US8883160B2 (en) 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US10202430B2 (en) * 2007-10-18 2019-02-12 Mayo Foundation For Medical Education And Research IgM-mediated receptor clustering and cell modulation
CA2853138A1 (fr) 2011-12-05 2013-06-13 Immunomedics, Inc. Utilisation therapeutique d'anticorps anti-cd22 pour induire une trogocytose
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
HUE057977T2 (hu) 2012-12-13 2022-06-28 Immunomedics Inc Ellenanyagok és SN-38 immunkonjugátumainak dózisai javított hatásossággal és csökkentett toxicitással
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CA2981543A1 (fr) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolement, detection, diagnostic et/ou caracterisation de cellules cancereuses trop-2 positives
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
US20170224837A1 (en) 2016-02-10 2017-08-10 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
CA3016917A1 (fr) 2016-04-27 2017-11-02 Immunomedics, Inc. Efficacite de conjugues medicament-anticorps anti-trop-2-sn-38 pour le traitement de tumeurs recidivantes/refractaires a des inhibiteurs de point de controle
CN110392570A (zh) 2017-03-27 2019-10-29 免疫医疗公司 用沙妥珠单抗格维替康和rad51抑制剂治疗表达trop-2的三阴性乳腺癌
WO2018187074A1 (fr) 2017-04-03 2018-10-11 Immunomedics, Inc. Administration par voie sous-cutanée de conjugués anticorps-médicament à titre de thérapie anticancéreuse

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0180171B1 (fr) † 1984-10-31 1992-04-08 Massachusetts Institute Of Technology Procédé pour rendre sensible une cellule ciblée à la lyse par les T-lymphocytes cytotoxiques
GB8626413D0 (en) † 1986-11-05 1986-12-03 Gilliland L K Antibodies
EP0305967B1 (fr) * 1987-09-02 1993-05-05 Ciba-Geigy Ag Conjugués d'interféron alpha avec immunoglobulines
DK8189A (da) * 1988-01-12 1989-07-13 Bunge Australia Antigen-antistof-konjugater, deres fremstilling og anvendelse
EP0334300A1 (fr) † 1988-03-21 1989-09-27 Neorx Corporation Utilisation d'anticorps monoclonaux et de conjugués de ceux-ci comme signaux pour diriger des cellules effecteurs sensibilisées sur des lieux tumoraux
DE3825615A1 (de) † 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
KR900005995A (ko) * 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
GB8907310D0 (en) † 1989-03-31 1989-05-17 Medical Res Council Heteroconjugates
IE63847B1 (en) * 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
AU651949B2 (en) * 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
JPH06502301A (ja) * 1990-08-29 1994-03-17 サントル　オスピタリエ　レジオナル　デ　ナント 安定タンパク質コアに結合されたタンパク質ポリリガンド

Also Published As

Publication number Publication date
DE69216899T2 (de) 1997-06-12
DE69216899D1 (de) 1997-03-06
EP0510949A3 (fr) 1992-12-09
ATE147993T1 (de) 1997-02-15
JPH07173071A (ja) 1995-07-11
DE69216899T3 (de) 2004-01-15
EP0510949B2 (fr) 2003-04-02
EP0510949B1 (fr) 1997-01-22
ES2099211T3 (es) 1997-05-16
CA2066810A1 (fr) 1992-10-24
JP3105629B2 (ja) 2000-11-06
EP0510949A2 (fr) 1992-10-28
ES2099211T5 (es) 2004-02-01

Similar Documents

Publication Publication Date Title
DK0510949T3 (da) Cytomoduleret konjugat indeholdende specifikke bindingspar.
EP0833666A3 (fr) Conjugues cytomodulants d'elements de paires de liaison specifiques
FI103410B1 (fi) Starburst-konjugaatteja
DE3782394D1 (de) Immobilisiertes, physiologisch aktives material.
SE8802818L (sv) Anordning foer stapling av satsvis anordnade foeremaal
DE68912318D1 (de) Membranverpackung.
ATE124611T1 (de) Verbesserungen an mattenklemmen.
AU4660789A (en) Polypeptide derivatives
ATE79135T1 (de) Bifunktionelle proteine.
ATE83889T1 (de) Tuberkulozides desinfektionsmittel.
GR1000118B (el) Συνθεσις 1,2-διοξετανων & ενδιαμεσαι ουσιαι δι αυτην.
NO881077D0 (no) Kjemo-radio-immuno-konjugater.
ES2058365T3 (es) 1,3,4,5-tetrahidrobenz(c,d)indoles.
DE69819644D1 (de) Bifunktionelle wasserlösliche Polymer-Derivate und diese enthaltende Komplexe
IT8019740A0 (it) Derivati benzoazepinici.
DK101196A (da) Histaminderivat, histamin-immunogen-konjugat samt antistof fremstillet mod konjugatet
NO883886L (no) Flammehemmende ethylencopolymermateriale.
DE58903624D1 (de) Strahlenhaertende, thermoaktivierbare klebstoffmischungen.
SU569308A1 (ru) Устройство дл ультразвуковой хирургии
FI880795A0 (fi) Banformat material, speciellt foer undertak.
PT92379A (pt) Metodo para a sintese de derivados polipeptidicos
ES267781Y (es) Cultivador con basculante de brazos perfeccionado.
NO884941D0 (no) Konjugat av metallothionein eller et metallothioneinfragment og et maalsoekende biologisk aktivt molekyl, som er anvendelig som mellomprodukt ved fremstilling av lignende merkede konjugater.
NO904235D0 (no) Forbedret cytotoksisk terapi.
ATE65012T1 (de) Aus partikeln bestehendes steriles material.